How to Boost Your Career and Help the Planet with Smart Workplace Habits

Life sciences executives and HR professionals often feel squeezed between urgent hiring goals, tighter budgets, and growing expectations to show credible sustainability leadership. At the same time, many teams still treat environmental impact at work as a facilities issue or a corporate report, leaving everyday decisions disconnected from measurable responsibility.

Unlock Interview Success with Better Communication

Award-winning author Charles Duhigg says that the candidates who shine in job interviews aren’t just the most qualified - they’re the best communicators. By showing authenticity, listening with empathy, and using thoughtful storytelling, you not only answer questions but build real connection and trust. These simple habits make you a more compelling candidate and transform interviews into meaningful conversations.

Teva Partners with Will Forte to Boost Huntington’s Disease Awareness

Teva Pharmaceuticals has enlisted actor and comedian Will Forte to help amplify its Honestly HD Huntington’s disease awareness campaign. Forte, best known for his work on Saturday Night Live, shares a personal perspective working alongside his brother-in-law Doug Modling, who lives with Huntington’s, in new campaign content that highlights the challenges of the disease and the support available to those affected.

Career expert warns job seekers to watch for interview red flags

In a recent CNBC Make It article, career expert Amanda Augustine highlights three key red flags candidates should watch for during interviews that could signal a toxic or poorly run workplace. These include situations where the hiring team can’t clearly define the role, interviewers avoid answering tough questions, or the overall tone and environment feel tense or unprofessional.

AbbVie signs drug pricing deal

AbbVie has struck a new drug pricing agreement with the White House that aligns with the administration’s most-favored-nation pricing initiative. Under the deal, the company will lower prices on select medicines for Medicaid and expand direct-to-patient offerings through the TrumpRx platform, while committing to $100 billion in U.S. research, development and capital investment over the next decade.

Career Expert Tips for Handling “Overqualified” Questions in Interviews

Being labeled “overqualified” can feel like a setback, but career experts say it’s often a soft rejection rather than a reflection of your ability. The key is to own your story—explain why you’re genuinely interested in the role, how your experience aligns with the company’s needs, and that you see long-term value in the position. Experts emphasize reframing your background as an asset and addressing potential employer concerns about fit, commitment, and career goals.

FDA Approves First Oral Wegovy Weight-Loss Pill

The U.S. Food and Drug Administration has approved a daily oral version of the popular weight-loss drug Wegovy, marking a major milestone in obesity treatment. This first-of-its-kind GLP-1 weight-loss pill from Novo Nordisk contains the same active ingredient, semaglutide, found in the injectable Wegovy and Ozempic, and is expected to expand access to those who prefer a pill over injections.

FDA Grants First-Line Approval for Enhertu Combination in HER2-Positive Breast Cancer

The U.S. Food and Drug Administration has approved AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu (fam-trastuzumab deruxtecan) in combination with Roche’s Perjeta as a first-line treatment for adults with unresectable or metastatic HER2-positive breast cancer confirmed by an FDA-approved test.

This new indication is supported by positive results from the Phase III DESTINY-Breast09 trial, which showed the Enhertu-Perjeta regimen significantly improved median progression-free survival (40.7 vs. 26.9 months) and reduced the risk of disease progression or death compared with the previous standard of care (taxane, trastuzumab and pertuzumab).

The approval expands Enhertu’s use beyond later-line settings, where it had previously earned FDA clearance, and could establish the combination as a new frontline standard of care in this aggressive oncology segment

Click here to read the entire article.

Do not share sensitive information with ChatGPT and other AI chatbots

Experts are warning users not to share sensitive information with ChatGPT and other AI chatbots because the data you type can be stored, analyzed, and used to improve models — and may not remain private. The key categories of information you should avoid sharing include personally identifiable details (name, address, IDs), intimate personal life details, medical and health information, confidential work or proprietary business data, and financial information like bank or credit card details.

UCB Announces Plan to Seek Regulatory Approval for Fintepla in CDKL5 Deficiency Disorder Following Positive Phase 3 Results

UCB announced that it will move forward with regulatory submissions for Fintepla® (fenfluramine) as a treatment for seizures associated with CDKL5 Deficiency Disorder (CDD), following highly positive results from its Phase 3 clinical trial. This represents a potential third indication for Fintepla, which is already approved for Dravet syndrome and Lennox-Gastaut syndrome.

Gen Z Is Rewriting Office Culture

As Gen Z returns to the office in growing numbers, they’re not just filling the physical space — they’re transforming it. According to a CNBC article, this generation is leaning into authenticity, mental health, and digital fluency, bringing new energy to work environments older generations may no longer frequent. From candid check-ins on well-being, to dressing casually and speaking in their own voice, to fully embracing AI tools as collaborators — Gen Z is reshaping corporate norms on its own terms.